GI Innovation Receives Minister of Health and Welfare Award for Contributions as an Innovative Pharmaceutical Company

GI Innovation announced on the 28th that it received the Minister of Health and Welfare Award for Innovative Pharmaceutical Companies at the '2023 Health Industry Performance Exchange Meeting.'

On the 27th, at the '2023 Health Industry Performance Exchange' held at EL Tower in Yangjae-dong, Seoul, Hong Junho, CEO of GI Innovation, is receiving the Minister of Health and Welfare Award for Innovative Pharmaceutical Companies.
[Photo by GI Innovation]

The Ministry of Health and Welfare and the Korea Health Industry Development Institute annually select and reward innovative pharmaceutical companies and contributors who have contributed to improving public health and developing the pharmaceutical industry. This year, GI Innovation and ST Pharm were selected among innovative pharmaceutical companies.

GI Innovation successfully licensed its allergy treatment drug 'GI-301' to Japan's Maruho last month, just seven months after its initial public offering (IPO) in March, in a deal worth a total of 298 billion KRW limited to the Japanese region. The company was recognized for its capabilities in innovative new drug development and global market entry, including large-scale clinical trials in Korea and the US for immuno-oncology drugs 'GI-101' and 'GI-102' and the formation of a global network, earning the Minister of Health and Welfare Award.

Additionally, Yoon Nari, Executive Director and Head of Clinical Development at GI Innovation, was recognized for her contributions to joint clinical trial agreements for next-generation immuno-oncology drugs with global big pharma such as MSD (Merck & Co., USA) and the technology transfer of GI-301 to Maruho in Japan, and was selected as an outstanding contributor in the export excellence category, receiving a commendation from the Institute Director.

On the 27th, at the '2023 Health Industry Performance Exchange' held at EL Tower in Yangjae-dong, Seoul, Yoon Nari, Executive Director of GI Innovation, is receiving an award for excellence in overseas export.

Hong Junho, CEO of GI Innovation, said, “GI Innovation has rapidly grown by solidifying its foundation through three technology transfers, large-scale funding of about 270 billion KRW, research and development (R&D) aligned with trends, and a global clinical network with the world’s top hospitals within six years of its establishment.” He added, “These factors seem to have been reflected in this evaluation, allowing us to receive the Minister of Health and Welfare Award as an innovative pharmaceutical company.” He further stated, “We will continue to do our best to grow as a company that can lead innovation and coexistence in the domestic pharmaceutical and bio ecosystem.”

This content was produced with the assistance of AI translation services.